RMD Stock Summary and Trading Ideas (Resmed | NYSE:RMD)

ResMed makes continuous positive airway pressure devices and the masks used to treat obstructive sleep apnea, a condition in which the airway repeatedly collapses during sleep. Devices make up about half of revenue, masks and accessories close to 40%, and residential care software the remainder. Growth depends on diagnosing more of the large untreated sleep apnea population and moving them onto therapy. The Americas contribute about two-thirds of device and mask revenue, with most of the rest from Europe, Japan, and Australia.

Resmed trades on the NYSE stock market under the symbol RMD.

As of November 3, 2026, RMD stock price declined to $227.08 with 2,026,418 million shares trading.

RMD has a beta of 0.19, meaning it tends to be less sensitive to market movements. RMD has a correlation of 0.01 to the broad based SPY ETF.

RMD has a market cap of $31.94 billion. This is considered a Large Cap stock.

Last quarter Resmed reported $1 billion in Revenue and $2.91 earnings per share. This beat revenue expectation by $23 million and exceeded earnings estimates by $.24.

In the last 3 years, RMD traded as high as $293.81 and as low as $140.81.

The top ETF exchange traded funds that RMD belongs to (by Net Assets): VTI, VOO, VO, IVV, SPY.

RMD has underperformed the market in the last year with a price return of -7.0% while the SPY ETF gained +11.7%. However, in the short term, RMD had mixed performance relative to the market. It has outperformed in the last 3 months, returning +7.9% vs +1.2% return in SPY. But in the last 2 weeks, RMD shares have been beat by the market, returning -5.3% compared to an SPY return of -1.6%.

RMD support price is $229.43 and resistance is $236.45 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that RMD shares will trade within this expected range on the day.